SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) today
announced its financial results for the period ended September 30, 2009.


Financial Review

The Company's loss for the nine month period ended September 30, 2009 decreased
by $957,537 to $3,369,200 ($0.03 per common share) from the loss of $4,326,737
($0.04 per common share) reported for the nine month period ended September 30,
2008. The primary reasons for the decrease in loss were decreases in research
and development costs, general and administration expenses, management and
consulting fees, and deemed interest charges offset by an increase in the stock
option expense and a decrease in interest income earned during the period. 


Capital Position

As of September 30, 2009 the working capital (current assets minus current
liabilities) of the Company was $3,279,422 ($5,803,377 as of December 31, 2008).
Subsequent to the recent financing which closed on October 29, 2009, the working
capital as of November 23, 2009 is estimated to be $4.3 million.


Outstanding securities as of September 30, 2009 totaled 134,680,497 common
shares, 17,097,000 share purchase warrants, and 12,017,500 common share options.



Outstanding securities as of November 23, 2009 are 152,905,004 common shares,
34,070,983 common share purchase warrants, and 12,017,500 common share options.


Dr. Alan Moore, President and CEO, commented as follows:

"As we progress through the year we are pleased to report that the cost-cutting
initiatives implemented in the first quarter have continued to keep the Company
in a positive financial position. These savings, in addition to the funds
recently raised, will ensure the Company's ability to complete the modified
REGENESIS Phase IIb stroke trial."


SCT will be issuing an aggregate of 3,695,000 stock options to the Company's
officers, Board of Directors, employees and Advisory Board members on November
24, 2009. The exercise price of the Options will be the closing price of
November 23, 2009. These options will expire no later than November 24, 2014
subject to applicable vesting provisions. These options were awarded in
accordance with the Company's Stock Option Plan. 


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024